Cover Image
市場調查報告書

生物仿製單株抗體 (mAb) 的全球市場預測 2018-2028年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab 的生物仿製

Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

出版商 Visiongain Ltd 商品編碼 275993
出版日期 內容資訊 英文 204 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
生物仿製單株抗體 (mAb) 的全球市場預測 2018-2028年:Infliximab / Rituximab / Trastuzumab / Trastuzumab/ Adalimumab / Bevacizumab / Abciximab 的生物仿製 Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab
出版日期: 2018年02月27日 內容資訊: 英文 204 Pages
簡介

全球生物仿製單株抗體(mAb)市場,估計在2018年到2028年的調查期間中會有19%的CAGR(複合年均增長率),到2023年將到達59億美元規模。

本報告針對全球生物仿製單株抗體 (mAb) 市場進行了調查,統整了市場預測、不同2級市場的收益預測、上市及開發中的不同生物仿製抗體的收益預測、主要國家市場的分析和預測、STEP分析及主要企業檔案等。

第1章 報告概要

第2章 簡介:生物仿製單株抗體

  • 天然抗體:免疫系統關鍵
  • 從血清治療到單株抗體 (mAbs)
  • mAb人源化
  • 生物製劑與生物仿製
  • 為什麼對生物仿製的需求很高?
  • 生物仿製開發檢討事項
  • 已經上市的生物仿製單株抗體

第3章 生物仿製單株抗體的全球市場預測

  • 現在的全球生物仿製單株抗體市場
  • 全球生物仿製mAb市場:收益估計
  • 全球生物仿製mAb市場、按化合物分類:收益、市場份額估計
  • 全球生物仿製mAb市場、按化合物分類:收益估計
  • 生物仿製mAb市場的成長推動因素和抑制因素
  • 生物仿製mAb市場的成長抑制因素

第4章 生物仿製mAb產品:上市藥物、研發中藥物

  • 已上市的生物仿製mAb
  • 生物仿製研發藥物

第5章 主要國家的生物仿製單株抗體市場

  • 主要國家市場的生物仿製mAb狀況?
  • 主要國家市場所佔分額在預測期間中會如何變化?
  • 印度:現為生物仿製mAb龍頭但預計成長趨緩
  • 俄羅斯:缺乏法規框架,在短期內可順利成長
  • 韓國:市場受惠於早期的生物仿製指南
  • 中國:細分化的生物仿製mAb市場
  • 巴西:ANVISA的生物仿製法規與EMA類似
  • EU的生物仿製mAb展望
  • 日本的生物仿製mAb展望
  • 美國的生物仿製mAb展望

第6章 各大公司

  • 生物仿製mAb開發協作
  • BioXpress
  • Celltrion
  • Harvest Moon
  • Genor Biopharma
  • Samsung Bioepsis
  • Mabion
  • Gene Techno Science
  • 印度的Biocon
  • Coherus Biosciences
  • BIOCAD
  • 主要公司和生物仿製mAb市場

第7章 生物仿製單株抗體市場定性分析

  • 優勢和劣勢
  • 機會和威脅
  • 影響生物仿製mAb市場的社會、技術、經濟與政治因素(STEP分析)

第8章 結論

  • 生物仿製單株抗體:全球市場
  • 市場、研發藥物中化合物的未來
  • 主要國家市場
  • 各大公司
  • 當前行業趨勢和預測

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0288

The global biosimilar monoclonal antibodies market is expected to reach $5.9bn in 2023 and is estimated to grow at a CAGR of 19% from 2016 to 2028.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 204-page report you will receive 72 tables and 74 figures- all unavailable elsewhere.

The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

Report Scope

  • Global Biosimilar Monoclonal Antibodies Market forecasts from 2018-2028
  • Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2028 for the market segmented by compound:
  • Infliximab
  • Rituximab
  • Abciximab
  • Trastuzumab
  • Adalimumab
  • Bevacizumab

image1

  • This report also shows revenue to 2028 for individual biosimilar mAb products in the market:
  • Remsima/Inflectra
  • Infimab
  • Reditux
  • BI695500
  • CT-P10
  • BI695501
  • FKB327
  • FKB238
  • Mabtas
  • AcellBia
  • Maball
  • Clotinab
  • Abcixirel
  • BCD-022
  • BCD-021
  • Herzuma
  • CANMAB/Hertraz
  • Our analyses show individual revenue forecasts to 2028 for these regional and national markets:
  • The US Biosimilar mAb Market
  • Japanese Biosimilar mAb Market
  • EU5 Biosimilar mAb Markets
  • BRIC and South Korea Biosimilar mAb Markets
  • Rest of the World Biosimilar mAb Market

This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline

Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market

Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Overview of Biosimilar Monoclonal Antibodies: R&D, Industry and Market
  • 1.2 Why You Should Read this Report
  • 1.3 How This Study Delivers
  • 1.4 Main Questions Answered by the Analysis
  • 1.5 Who is This Investigation For?
  • 1.6 Method of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQs)
  • 1.8 Associated visiongain Reports
  • 1.9 About visiongain

2. Introduction to Biosimilar Monoclonal Antibodies

  • 2.1 Natural Antibodies: Key to the Immune System
  • 2.2 From Serum therapy to Monoclonal Antibodies
  • 2.3 Humanising the mAb
  • 2.4 Biologics (Biological Drugs) and Biosimilars
  • 2.5 Why are Biosimilars in High Demand?
  • 2.6 Considerations for the Development of Biosimilars
    • 2.6.1 Biologics and Biosimilars Are Large, Complex Molecules
    • 2.6.2 How Much of a Concern is Immunogenicity?
  • 2.7 Biosimilar Monoclonal Antibodies Currently on the Market

3. The Global Market for Biosimilar Monoclonal Antibodies, 2018-2028

  • 3.1 The Present Global Market for Biosimilar Monoclonal Antibodies
  • 3.2 The Global Market for Biosimilar mAbs: A Revenue Forecast, 2016-2028
  • 3.3 The Global Market for Biosimilar mAbs by Compound: Predictions for Revenue and Market Share in 2023 and 2028
  • 3.4 The World Market for Biosimilar mAbs by Compound: Revenue Forecasts, 2016-2028
    • 3.4.1 Will Biosimilar Versions of Monoclonal Antibodies Capture a Large Proportion of the Market?
    • 3.4.2 Biosimilar Infliximab
    • 3.4.3 Biosimilar Rituximab
    • 3.4.4 Biosimilar Abciximab
    • 3.4.5 Biosimilar Trastuzumab
    • 3.4.6 Biosimilar Adalimumab
    • 3.4.7 Biosimilar Bevacizumab
  • 3.5 Drivers and Restraints for the Biosimilar mAb market 2018-2028
    • 3.5.1 Driving Factors of the Biosimilar mAb Market 2018-2028
  • 3.6 Restraining Factors of the Biosimilar mAb Market 2018-2028

4. Individual Biosimilar mAb Products: Marketed and Pipeline Drugs, 2018-2028

  • 4.1 Biosimilar mAbs on the Market in 2017
    • 4.1.1 Celltrion's Remsima/ Hospira's Inflectra/ Egis' Flammegis (Infliximab): The First Official Biosimilar Monoclonal Antibody
    • 4.1.2 Infimab (Infliximab): Launched a Quarter Ahead of Schedule
    • 4.1.3 Dr Reddy's Reditux (Rituximab): No Application for EU or US Approval
    • 4.1.4 Intas Pharmaceuticals' Mabtas (Rituximab)
    • 4.1.5 AcellBia (Rituximab): Sales in Russia Generating Large Revenue Figures
    • 4.1.6 MABALL: Faces Competition from other Biosimilar Rituximabs in India
    • 4.1.7 Isu Abxis' Clotinab (abciximab):
    • 4.1.8 AbcixiRel: The First Indian Abciximab Biosimilar
    • 4.1.9 Herzuma (Trastuzumab): Approved in South Korea
    • 4.1.10 CANMAb/Hertraz (Trastuzumab)
  • 4.2 Pipeline Biosimilars
    • 4.2.1 BI695500 (Rituximab)
    • 4.2.2 CT-P10 (Rituximab): Celltrion's Reputation for Biosimilars will Assist Sales
    • 4.2.3 Boehringer Ingelheim's BI695501 (Adalimumab)
    • 4.2.4 BCD-022 (Trastuzumab): Approved in Russia
    • 4.2.5 Fujifilm Kyowa Kirin Biologics' FKB327 (Adalimumab)
    • 4.2.6 Fujifilm Kyowa Kirin Biologics' FKB238 (Bevacizumab)
    • 4.2.7 BCD-021 (Bevacizumab): Russia Will Contribute the Most Revenue

5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2018-2028

  • 5.1 What Were the Leading National Markets for Biosimilar mAbs in 2017?
  • 5.2 How Will National Market Shares Change Over the Forecast Period?
  • 5.3 India: The Current Leading Nation for Biosimilar mAbs but Growth Will Slow
    • 5.3.1 India Releases New Biosimilar Development Guidelines
    • 5.3.2 Indian Biosimilar Submarket Forecast 2016-2028
  • 5.4 Russia: Lack of Regulatory Framework Works Well in the Short Term
    • 5.4.1 Russian Government Backed 'Pharma 2020' Initiative
    • 5.4.2 Russian Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.4 South Korean Market Has Benefitted from Early Biosimilar Guidelines
    • 5.4.1 Significant Investment in Biosimilars in South Korea
    • 5.4.2 South Korean Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.5 China: A Fragmented Biosimilar mAb Market
    • 5.5.1 Chinese FDA Publishes Finalised Biosimilar Guidelines in 2017
    • 5.5.2 China Biosimilar mAb Revenue Forecast, 2016-2028
  • 5.6 Brazil: ANVISA's Biosimilar Regulations Are Similar the EMA's
    • 5.6.1 Brazil Biosimilar mAb Revenue Forecast 2016-2028
  • 5.7 The Outlook for Biosimilar mAbs in the EU 2016-2028
    • 5.7.1 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar mAbs
    • 5.7.2 Biosimilar mAbs in the EU5: Revenue Forecasts, 2016-2028
    • 5.7.3 Germany: The Current EU Leader
    • 5.7.4 France: Will the Uptake of Biosimilar mAbs be Restricted?
    • 5.7.5 UK: NICE Recommends Use of Remsima for Certain Indications
    • 5.7.6 Italy: Healthcare Spending Cuts Will Drive Growth
    • 5.7.7 Spain: High Biosimilar mAb Discounts Expected
  • 5.8 The Outlook for Biosimilar mAbs in Japan
    • 5.8.1 Regulations for Naming Biosimilars
    • 5.8.2 Biosimilar mAb Market Activity in Japan
    • 5.8.3 Japanese Biosimilar Submarket Forecast 2016-2028
  • 5.9 US Biosimilar mAb Outlook: None Currently on the Market
    • 5.9.1 US FDA Biosimilar Guidelines were Released in 2015
    • 5.9.2 Legal Challenges for Biosimilars in the US
    • 5.9.3 State Regulation of Biosimilar Substitution
    • 5.9.4 The US Biosimilar mAb Market Revenue Forecast, 2016-2028
    • 5.9.5 The Mexico Biosimilar mAb Market Revenue Forecast, 2016-2028
    • 5.9.6 The Canada Biosimilar mAb Market Revenue Forecast, 2016-2028

6. Leading Companies in the Biosimilar Monoclonal Antibodies Market

  • 6.1 Collaboration in Biosimilar mAb Development
  • 6.2 BioXpress
  • 6.3 Celltrion
  • 6.4 Harvest Moon
  • 6.5 Genor Biopharma
  • 6.6 Samsung Bioepsis
  • 6.7 Mabion
  • 6.8 Gene Techno Science
  • 6.9 India's Biocon
  • 6.10 Coherus Biosciences
  • 6.11 BIOCAD
  • 6.12 Big Pharma and the Biosimilar mAb Market

7. Qualitative Analysis of Biosimilar Monoclonal Antibodies Market

  • 7.1 Strengths and Weaknesses of the Biosimilar Monoclonal Antibodies Market, 2016-2028
    • 7.1.1 Global Demand for Affordable Biopharmaceuticals has Never Been Greater
    • 7.1.2 Adoption of Biosimilar mAbs will be Proportional to the Rate of Discount
    • 7.1.3 Approval Pathways are Now Established in Developed Markets
    • 7.1.4 Complexity of Protein Molecules Leads to Technical Challenges
    • 7.1.5 Doctor and Patient Confidence May Take Time
  • 7.2 Opportunities and Threat Facing the Biosimilar Monoclonal Antibodies Market, 2016-2028
    • 7.2.1 Market Opportunities from Patent Expiries and a Well-Stocked Pipeline
    • 7.2.2 Substitution may Not Occur Automatically
    • 7.2.3 Biobetters Offer a Serious Threat to the Production and Uptake of Biosimilars
  • 7.3 Social and Technological Forces Influencing the Biosimilar Monoclonal Antibodies Market 2016-2028
    • 7.3.1 Social Factors: Driving or Restraining the Market?
    • 7.3.2 Technological Factors Concentrate on Reducing Costs and Increasing Ease of Production
    • 7.3.3 Economic Pressures Raise Demand for Biosimilar mAbs
    • 7.3.4 Political Issues: Stringent Regulations Hurdles to Market Entry

8. Conclusions

  • 8.1 Biosimilar Monoclonal Antibodies: World Market, 2016-2028
  • 8.2 Future of Compounds on the Market and in the Pipeline
  • 8.3 Leading National Markets for Biosimilar Monoclonal Antibodies 2017, 2023, 2028
  • 8.4 Leading Companies in the Biosimilar mAb Market
  • 8.5 Current and Expected Industry Trends 2016-2028
    • 8.5.1 Cost Control of Healthcare Will Work in Favour mAbs
    • 8.5.2 Upcoming Patent Expiries in Developed Markets Offer Large Market Potential
    • 8.5.3 Complex Production Processes are a Restraining Factor
    • 8.5.4 Clinician and Patient Confidence Must be Maximized to Ensure Uptake
    • 8.5.5 Biobetters Pose a Threat

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B
  • Visiongain report evaluation form

List of Tables

  • Table 2.1 Classification of Monoclonal Antibodies
  • Table 2.2 Murine Monoclonal Antibodies on the Market
  • Table 2.3 Chimeric Monoclonal Antibodies on the Market
  • Table 2.4 Humanised Monoclonal Antibodies on the Market
  • Table 2.5 Fully Human Monoclonal Antibodies on the Market
  • Table 2.6 Revenue of Originator Monoclonal Antibody Products in 2016
  • Table 3.1 Global Biosimilar mAbs Market Forecast 2016-2028: Revenue ($m), AGR (%), CAGR (%)
  • Table 3.2 Global Market for Biosimilar mAbs: Revenues ($m) and Market Shares (%) by Reference Compound, 2017, 2023 and 2028
  • Table 3.3 EU and US Patent Expiry Dates for the Main mAb Reference Products
  • Table 3.4 Global Biosimilar mAbs Market Forecast by Reference Compound: Revenue ($m), AGR (%), CAGR (%), 2016-2028
  • Table 3.5 Biosimilar Infliximab: Compounds Awaiting Approval in the Pipeline
  • Table 3.6 Global Biosimilar Infliximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.7 Biosimilar Rituximab: Compounds (Marketed or in the Pipeline), 2018
  • Table 3.8 Global Biosimilar Rituximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.9 Biosimilar Abciximab: Compounds (Marketed or in the Pipeline), 2018
  • Table 3.10 Global Biosimilar Abciximab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.11 Biosimilar Trastuzumab: Compounds Marketed and in the Pipeline, 2018
  • Table 3.12 Global Biosimilar Trastuzumab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 3.13 Biosimilar Adalimumab: Compounds (Marketed or in the Pipeline) 2018
  • Table 3.14 Global Biosimilar Adalimumab Market Forecast 2016-2028: Revenue ($m), AGR (%), and CAGR (%)
  • Table 3.15 Biosimilar Bevacizumab: Compounds (Marketed or in the Pipeline) 2018
  • Table 3.16 Global Biosimilar Bevacizumab Market Forecast 2016-2028: Revenue ($m), AGR (%) and CAGR (%)
  • Table 4.1 Biosimilar mAbs on the Market in 2017: Revenues ($m) and Market Shares (%)
  • Table 4.2 Remsima/Inflectra/Flammegis (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.3 Infimab (Infliximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.4 Reditux (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2027
  • Table 4.5 Mabtas (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.6 Biocad Distribution Partners for AcellBia, 2017
  • Table 4.7 AcellBia (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.8 MABALL (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.9 Clotinab (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.10 AbcixiRel (Abciximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.11 Herzuma (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.12 CANMAb/Hertraz (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.13 BI695500 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.14 CT-P10 (Rituximab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2027
  • Table 4.15 BI695501 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2028
  • Table 4.16 BCD-022 (Trastuzumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2016-2028
  • Table 4.17 FKB327 (Adalimumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2017-2028
  • Table 4.18 FKB238 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2020-2028
  • Table 4.19 BCD-021 (Bevacizumab) Forecast: Revenue ($m), Market Share (%), AGR (%) and CAGR (%), 2018-2028
  • Table 5.1 Leading National Markets for the Global Biosimilar mAb Industry, 2017
  • Table 5.2 Leading National Markets for the Global Biosimilar mAb Industry, 2017, 2023, 2028
  • Table 5.3 The Indian Biosimilar Mab Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.4 The Russian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.5 The South Korean Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.6 The Chinese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.7 The Brazilian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.8 The EU5 Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Table 5.9 The German Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.10 The French Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.11 The UK Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.12 The Italian Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.13 The Spanish Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.14 The Japanese Biosimilar mAb Market: Revenue ($m), Annual Growth (%) and CAGR (%) Forecast, 2016-2028
  • Table 5.15 Finalised FDA Biosimilar Guidelines, 2015
  • Table 5.16 The US Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 5.17 The Mexico Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 5.17 The Canada Biosimilar mAb Market: Revenue ($m) and Annual Growth (%) Forecast, 2017-2028
  • Table 6.1 Companies in the Biosimilar mAb Industry by Number of Compounds in Development, 2017
  • Table 6.2 Selected Collaborations for Biosimilar mAb Development, 2009-2017
  • Table 6.3 BioXpress: Compounds in the Pipeline, 2018
  • Table 6.4 Tests Carried Out by BioXpress During Biosimilar mAb Development, with Objectives
  • Table 6.5 Compounds in Celltrion's Pipeline: Compound Name, Generic Name, Development Stage and Anticipated Year of Approval, 2017
  • Table 6.6 Genor Biopharma: Biosimilar mAbs Pipeline, 2017
  • Table 6.7 Mabion: Compounds in the Pipeline and Their Development Stage, 2017
  • Table 6.8 Gene Techno Science: Revenue ($m), from 2013-2017
  • Table 6.9 Biocon: Compounds in the Pipeline and Their Stage of Development, 2017
  • Table 6.10 Big Pharma's Positions in the Biosimilar mAb Industry, 2017
  • Table 7.1 Strengths and Weaknesses of the Biosimilar mAb Market, 2016-2028
  • Table 7.2 Opportunities and Threats Facing the Biosimilar mAb Market, 2016-2028
  • Table 7.3 Social and Technological Factors Influencing the Biosimilar mAb Market, 2016-2028

List of Figures

  • Figure 1.1 Main Compound Classes of Biosimilar mAbs, 2018
  • Figure 2.1 Structure of an Antibody
  • Figure 3.1 Global Biosimilar mAbs Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.2 The Biosimilar mAb Market: Market Share (%) by compound in 2017
  • Figure 3.3 The Biosimilar mAb Market: Market Share (%) by compound in 2023
  • Figure 3.4 The Biosimilar mAb Market: Market Share (%) by compound in 2028
  • Figure 3.5 Global Biosimilar Infliximab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.6 Global Biosimilar Rituximab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.7 Global Biosimilar Abciximab Market Forecast: Revenue ($m), AGR (%), and CAGR (%)
  • Figure 3.8 Global Biosimilar Trastuzumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.9 Global Biosimilar Adalimumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.10 Global Biosimilar Bevacizumab Market Forecast: Revenue ($m), 2016-2028
  • Figure 3.11 Drivers and Restraints for the Global Biosimilar mAb market 2016-2028
  • Figure 4.1 Biosimilar mAb Versions on the Market: Market Share (%) 2017
  • Figure 4.2 Biosimilar mAb Versions on the Market: Market Share (%) 2023
  • Figure 4.3 Biosimilar mAb Versions on the Market: Market Share (%) 2028
  • Figure 4.4 Remsima/Inflectra/Flammegis (Infliximab): Revenue Forecast ($m), 2016-2028
  • Figure 4.5 Remsima/Inflectra/Flammegis (Infliximab): AGR Forecast (%), 2016-2028
  • Figure 4.6 Infimab (Infliximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.7 Infimab (Infliximab): AGR Forecast (%) 2016-2028
  • Figure 4.8 Reditux (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.9 Reditux (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.10 Mabtas (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.11 Mabtas (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.12 AcellBia (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.13 AcellBia (Rituximab): AGR Forecast(%) 2016-2028
  • Figure 4.14 MABALL (Rituximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.15 MABALL (Rituximab): AGR Forecast (%) 2016-2028
  • Figure 4.16 Clotinab (Abciximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.17 Clotinab (Abciximab): AGR Forecast (%) 2016-2028
  • Figure 4.18 AbcixiRel (Abciximab): Revenue Forecast ($m) 2016-2028
  • Figure 4.19 AbcixiRel (Abciximab): AGR Forecast (%) 2016-2028
  • Figure 4.20 Herzuma (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.21 Herzuma (Trastuzumab): AGR Forecast (%) 2016-2028
  • Figure 4.22 CANMAb/Hertraz (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.23 CANMAb/Hertraz (Trastuzumab): AGR Forecast (%) 2016-2028
  • Figure 4.24 BI695500 (Rituximab): Revenue Forecast ($m) 2018-2028
  • Figure 4.25 BI695500 (Rituximab): AGR Forecast (%) 2019-2028
  • Figure 4.26 CT-P10 (Rituximab): Revenue Forecast ($m) 2019-2028
  • Figure 4.27 CT-P10 (Rituximab): AGR Forecast (%) 2019-2028
  • Figure 4.28 BI695501 (Adalimumab): Revenue Forecast ($m) 2018-2028
  • Figure 4.29 BI695501 (Adalimumab): AGR Forecast (%) 2019-2028
  • Figure 4.30 BCD-022 (Trastuzumab): Revenue Forecast ($m) 2016-2028
  • Figure 4.31 BCD-022 (Trastuzumab): AGR Forecast (%) 2017-2028
  • Figure 4.32 FKB327 (Adalimumab): Revenue Forecast (%) 2018-2028
  • Figure 4.33 FKB327 (Adalimumab): AGR Forecast (%) 2019-2028
  • Figure 4.34 FKB238 (Adalimumab): Revenue Forecast ($m) 2020-2028
  • Figure 4.35 FKB238 (Adalimumab): AGR Forecast (%) 2022-2028
  • Figure 4.36 BCD-021 (Bevacizumab): Revenue Forecast ($m) 2017-2028
  • Figure 4.37 BCD-021 (Bevacizumab): AGR Forecast (%) 2018-2028
  • Figure 5.1 The Biosimilar Mab Market by Country: Market Shares (%) of Revenue, 2017
  • Figure 5.2 The Biosimilar Mab Market: National Submarket Shares (%), 2023
  • Figure 5.3 The Biosimilar Mab Market: National Submarket Shares (%), 2028
  • Figure 5.4 The Indian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.5 The Russian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.6 The South Korean Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.7 The Chinese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.8 The Brazilian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.9 The EU5 Biosimilar mAb Market: Grouped Revenue Forecast ($m), 2016-2028
  • Figure 5.10 The EU5 Biosimilar mAb Market: Revenue Forecasts ($m) by Country, 2016-2028
  • Figure 5.11 The German Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.12 The French Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.13 The UK Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.14 The Italian Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.15 The Spanish Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.16 The Japanese Biosimilar mAb Market: Revenue Forecast ($m), 2016-2028
  • Figure 5.17 Biosimilar mAbs in the US: Revenue Forecast ($m), 2017-2028
  • Figure 5.18 Biosimilar mAbs in the Mexico: Revenue Forecast ($m), 2016-2028
  • Figure 5.19 Biosimilar mAbs in the Canada: Revenue Forecast ($m), 2016-2028
  • Figure 6.1 Prominent Companies in the Biosimilar mAb Industry: Share (%) of the Pipeline (2017)
  • Figure 8.1 Prominent Compounds in the Biosimilar mAb Market: Comparison of Revenues ($m), 2017, 2023 and 2028
  • Figure 8.2 Forecasted Biosimilar mAbs: Comparison of Revenues ($m), 2017, 2023 and 2028
  • Figure 8.3 Leading National Markets: Revenues ($m), 2017, 2023 and 2028
  • Figure 8.4 Prominent Companies in the Biosimilar mAb Industry: Number of Products in Current Development or in the Pipeline, 2017

Companies Listed

  • Abbott
  • AbbVie
  • Aché
  • Actavis
  • AET BioTech
  • Alexion Pharmaceuticals
  • Allergan
  • Alvogen
  • Alvotech
  • Amgen
  • Apotex
  • Aprogen
  • Array Bridge
  • AstraZeneca
  • Aurobindo Pharma Limited
  • Axis Biotec Brasil
  • Baliopharm GmbH
  • Baxalta
  • Bayer
  • Binex
  • BIO
  • Bio Farma
  • BIOCAD
  • Biocerus
  • Biocon
  • Biogen Idec
  • Bio-Manguinhos
  • Bionovis
  • BioXpress Therapeutics
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Catalent Pharma Solutions
  • Cell Therapeutics
  • Celltrion
  • Celon Pharma Łomianki
  • Chugai
  • CinnaGen
  • CinnaGen
  • Coherus BioSciences
  • Daiichi Sankyo
  • DM Bio
  • Dong-A Pharma
  • Dr Reddy's
  • Dyadic International, Inc.
  • Egis Pharmaceuticals
  • Eisai
  • Eli Lilly
  • Emcure
  • EMS
  • Epirus Biopharmaceuticals
  • Farmasa
  • Fresenius
  • Fujifilm
  • Fujifilm Kyowa Kirin Biologics
  • Gedeon Richter
  • Gene Techno Science
  • Genentech
  • GeneTechno Science
  • Genexo
  • Genor Biopharma
  • GlaxoSmithKline
  • Glycotope
  • Hanwha Chemical
  • Harvest Moon
  • Hetero Group
  • Hospira
  • Hypermarcas
  • iBio
  • IBSS Biomed
  • ImClone LLC
  • Instas Pharmaceuticals
  • Instituto Vital Brazil
  • Intas Biopharmaceuticals
  • IPCA Labs
  • Isu Abxis
  • Janssen
  • JHL Biotech
  • Johnson & Johnson
  • Kyowa Hakko Kirin
  • Laboratorio Elea
  • Laboratorios Liomont
  • LG Life Sciences
  • Lonza
  • Mabion
  • Mabtech Limited
  • mAbxience
  • MedImmune
  • Merck & Co.
  • Merck (MSD)
  • Merck Serono
  • Millhouse LLC
  • Mitsubishi Tanabe
  • Mochida Pharmaceutical
  • Momenta Pharmaceuticals
  • Mustafa Nevzat Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nichi-Iko Pharmaceutical Co.
  • Nippon Kayaku
  • Novartis
  • Oncobiologics
  • Otsuka Pharmaceutical
  • Parexel
  • Paul-Ehrlich Institute of Germany
  • Pfizer
  • PharmaPraxis
  • Pharmstandard
  • PhRMA
  • PlantForm
  • Polfarmex
  • ProBioGen
  • Probiomed
  • QuantiaMD
  • Quintiles
  • Ranbaxy Laboratories
  • Regeneron Pharmaceuticals
  • Reliance GeneMedix
  • Reliance Life Sciences
  • Roche
  • Samsung Bioepis
  • Samsung Biologics
  • Sandoz
  • Sanofi
  • Schnell
  • Seattle Genetics
  • Shanghai CP Guojian
  • Shionogi
  • Sorrento Therapeutics
  • Spectrum Pharmaceuticals
  • Stada Arzneimittell AG
  • Synthon
  • Takeda
  • Teva Pharmaceutical
  • TL Biopharmaceutical AG
  • UCB
  • União Química
  • Viropro
  • Walvax Biotechnology
  • Wyeth
  • Zenotech Laboratories
  • Zhejiang HISUN Pharmaceuticals Co. Ltd. (HISUN)
  • Zhejiang Huahai Pharmaceutical
  • Zydus-Cadila

List of Organizations Mentioned in the Report

  • Agence française de sécurité sanitaire des produits de santé (ANSM)
  • Agência Nacional de Vigilância Sanitária (ANVISA)
  • Central Drugs Standard Control Organisation and the Department of Biotechnology
  • Chinese Centre for Drug Evaluation (CDE)
  • Cour des Comptes (France)
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Fraunhofer Center for Molecular Biology
  • Health Canada
  • India Brand Equity Foundation
  • Israel Institute for Biological Research (IIBR)
  • Korean Food and Drug Administration (KFDA)
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Ministry of Food and Drug Safety (South Korea)
  • Ministry of Health of the Russian Federation
  • Ministry of Health, Labour and Welfare (MHLW)
  • National Institute for Health and Care Excellence (NICE)
  • National Institute for Health Research Horizon Scanning Centre
  • Norwegian Medical Agency
  • Scientific Centre for Expertise of Medicinal Application Products (Russia)
  • Spanish Ministry of Health
  • State Food and Drug Administration (SFDA)
  • The Cancer Centre Bahamas
  • The European Medicines Agency (EMA)
  • The German Generics Association Pro Generika
  • UCAB (The Utrecht Centre of Excellence for Affordable Biotherapeutics for Public Health
  • Washington Legal Foundation
  • World Health Organization (WHO)
Back to Top